ALMS
ALMS
Positions held
Your positionsALMS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
2026-09-10 · Top Premarket Gainers
2026-09-10 · Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing
2026-09-09 · Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
2026-09-04 · Alumis to Participate in Upcoming September Investor Conferences
2026-09-03 · Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
2026-09-03 · Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
2026-09-03 · Guggenheim Downgrades Alumis to Neutral From Buy
2026-09-03 · Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
2026-09-03 · Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints
2026-09-02 · Sector Update: Healthcare Stocks Advance Late Afternoon
Price (daily)
Full chart · RSI · MACD · patterns